Search company, investor...

Founded Year

2010

Stage

IPO | IPO

Date of IPO

7/16/2021

Market Cap

1.19B

Stock Price

9.71

About SD Biosensor

SD Biosensor (KOSE:137310) manufactures medical equipment. It works on the research and development of immunological and molecular diagnostics and blood glucose self-monitoring systems. It was founded in 2010 and is based in Gyeonggi-do, South Korea.

Headquarters Location

C-4&5 Floor, 16, Deogyeong-daero 1556beon-gil, Yeongtong-gu

Gyeonggi-do, 16690,

South Korea

82-31-300-0400

Loading...

Loading...

SD Biosensor Patents

SD Biosensor has filed 13 patents.

The 3 most popular patent topics include:

  • transcription factors
  • evolutionary biology
  • biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/30/2016

10/24/2023

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Grant

Application Date

11/30/2016

Grant Date

10/24/2023

Title

Related Topics

Molecular biology, DNA, Biotechnology, Genetics, Molecular biology techniques

Status

Grant

Latest SD Biosensor News

The Influenza Diagnostics Market size to grow at a CAGR of 6.95% from 2022 to 2027|Abbott Laboratories, Becton Dickinson, and Co., BICO Group AB and more among the key companies in the market -Technavio

Nov 10, 2023

|Abbott Laboratories, Becton Dickinson, and Co., BICO Group AB and more among the key companies in the market -Technavio News provided by Share this article Share toX NEW YORK, Nov. 9, 2023 /PRNewswire/ -- The influenza diagnostics market is estimated to grow at a CAGR of 6.95% from 2022 to 2027. The market size is forecast to increase by USD 466.18 million, according to Technavio. The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Technavio report analyzes the market's competitive landscape and offers information on several market vendors including - Abbott Laboratories, Becton Dickinson, and Co., BICO Group AB, Bio Rad Laboratories Inc., Biocartis Group NV, bioMerieux SA, Danaher Corp., DiaSorin SpA, F. Hoffmann La Roche Ltd., Hologic Inc., Princeton BioMeditech Corp., QIAGEN NV, Response Biomedical Corp., SA Scientific Ltd., Sd Biosensor Inc., Sekisui Chemical Co. Ltd., Siemens Healthineers AG, Tecan Trading AG, Thermo Fisher Scientific Inc., and Quidelortho Corp.– Download a Sample Report Influenza Diagnostics Market Insights - Vendors: 15+, Including Abbott Laboratories, Becton Dickinson, and Co., BICO Group AB, Bio Rad Laboratories Inc., Biocartis Group NV, bioMerieux SA, Danaher Corp., DiaSorin SpA, F. Hoffmann La Roche Ltd., Hologic Inc., Princeton BioMeditech Corp., QIAGEN NV, Response Biomedical Corp., SA Scientific Ltd., Sd Biosensor Inc., Sekisui Chemical Co. Ltd., Siemens Healthineers AG, Tecan Trading AG, Thermo Fisher Scientific Inc., and Quidelortho Corp., among others Coverage: Parent market analysis; key drivers, major trends, and challenges; customer and vendor landscape; vendor product insights and recent developments; key vendors; and market positioning of vendors Segments: end-user (hospitals and diagnostic laboratories, academic and research centers, and homecare), type (point-of-care testing, immunodiagnostics, and molecular diagnostics), and geography (North America, Europe, Asia, and Rest of World (ROW)) Influenza Diagnostics Market – Market Dynamics Key Driver The early detection of influenza is a key factor driving market growth. Influenza, a prevalent viral infection, impacts a substantial portion of the global population annually. The increasing number of influenza cases has resulted in a greater demand for diagnostic tests to detect and manage the infection early. Furthermore, during influenza outbreaks, the number of influenza cases increases significantly, increasing the need for diagnostic tests to detect and monitor the spread of the virus. In response to this seasonal demand, diagnostic manufacturers are providing healthcare facilities with influenza diagnostic kits and tests to meet their growing testing needs. Hospitals, clinics, and laboratory systems are experiencing an increased presence of influenza strains, necessitating reliable and efficient diagnostics to manage more significant numbers of patients effectively during the influenza season Hence, early detection of influenza is expected to drive market growth during the forecast period. Major Trends The rising adoption of rapid diagnostic products in physician office laboratories is a major trend in the market. Manufacturers in target markets are increasingly focused on providing affordable and rapid testing using immunoassays and molecular diagnostics. These tests are widely used in clinic medical laboratories to provide rapid results and timely diagnoses during patient visits. Contributions to value-based care programs and quality-payment initiatives drive increased laboratory work in clinics, thereby reducing the need for patient hospitalization. This has helped accelerate the introduction of laboratory testing practices, increasing demand for influenza testing products in such laboratories. For example, in the US, there has been a steady increase in the placement of laboratories in clinics due to the benefits of Medicare billing. Hence, these factors are expected to drive market growth during the forecast period. Significant Challenge The lack of laboratory infrastructure in developing regions is a significant challenge restricting market growth. Developing countries face challenges in establishing and maintaining well-equipped influenza diagnostic laboratories. Limited access to diagnostic resources makes it difficult to diagnose influenza cases quickly and accurately. This challenge is due to inadequate infrastructure, lack of trained staff, and limited diagnostic tools and reagents available. In addition, remote areas often lack adequate testing facilities, making timely influenza diagnosis impossible, especially in areas without established healthcare systems. As a result, this challenge hinders disease surveillance efforts and the ability to track and respond to influenza outbreaks effectively. Hence, these factors are expected to restrict market growth during the forecast period. What are the key data covered in this Influenza Diagnostics Market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the influenza diagnostics market between 2023 and 2027 Precise estimation of the size of the influenza diagnostics market and its contribution to the market with a focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the influenza diagnostics market across North America, Europe, Asia, and the Rest of the World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of influenza diagnostics market vendors. Gain instant access to 17,000+ market research reports. Related Reports The companion diagnostics market is estimated to grow at a CAGR of 22.59% between 2022 and 2027. The market size is forecast to increase by USD 11,029.63 million. The cancer diagnostics market is estimated to grow at a CAGR of 11.3% between 2022 and 2027. The market size is forecast to increase by USD 12,626.21 million. Table of Contents About US Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

SD Biosensor Frequently Asked Questions (FAQ)

  • When was SD Biosensor founded?

    SD Biosensor was founded in 2010.

  • Where is SD Biosensor's headquarters?

    SD Biosensor's headquarters is located at C-4&5 Floor, 16, Deogyeong-daero 1556beon-gil, Yeongtong-gu, Gyeonggi-do.

  • What is SD Biosensor's latest funding round?

    SD Biosensor's latest funding round is IPO.

  • Who are the investors of SD Biosensor?

    Investors of SD Biosensor include Bill & Melinda Gates Foundation.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.